News & Events
-
June 28, 2023
C-Path’s TRxA Announces $750,000 in Research Awards to Accelerate its First Drug Development Projects
TUCSON, Ariz., June 28, 2023 — Critical Path Institute’s (C-Path) Translational Therapeutics Accelerator (TRxA) announced today its first two research grants supporting academic scientists in advancing novel compounds through the drug development process. Launched in June 2022, TRxA is a global drug discovery and development program focused on supporting academic scientists in defining optimal strategies...... -
September 5, 2022
CP-RND PR post
The standard Lorem Ipsum passage, used since the 1500s “Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse...... -
June 9, 2022
C-Path Launches Unique Translational Therapeutics Accelerator with Support from Cottrell Foundation
The global accelerator will transform academic discoveries to drug development opportunities TUCSON, Ariz., June 9, 2022 — Critical Path Institute (C-Path) today announced it has been awarded a grant from the Frederick Gardner Cottrell Foundation, a non-profit organization established by Research Corporation Technologies, Inc. (RCT) that provides financial support for scientific research and educational programs,...... -
January 27, 2021
C-Path Announces SHIP-MD 2021 Virtual Workshop
Multi-stakeholder event will focus on national innovation ecosystem for pediatric medical device development TUCSON, Ariz., January 14, 2021 — The Critical Path Institute (C-Path) in collaboration with the U.S. Food and Drug Administration’s (FDA) Center for Devices and Radiological Health (CDRH) AdvaMed, the American Academy of Pediatrics (AAP) and multiple pediatric health system leaders,...... -
March 19, 2020
C-Path Receives FDA Grant to Establish Rare Disease Clinical Outcome Assessment Consortium
The U.S. Food and Drug Administration’s Center for Drug Evaluation and Research has funded a cooperative agreement to establish a Rare Disease Clinical Outcome Assessment Consortium. The grant was awarded to C-Path with the NORD as a sub-awardee. The first step taken toward the establishment of the new consortium has been the creation of the Rare Disease Subcommittee within C-Path’s Patient-Reported Outcome (PRO) Consortium.